Nose M, Katoh M, Okada N, Kyogoku M, Okada H
Department of Pathology, Tohoku University School of Medicine, Sendai, Japan.
Immunology. 1990 Jun;70(2):145-9.
A 20,000 molecular weight (MW) homologous restriction factor (HRF20), detected by 1F5 monoclonal antibody (mAb), is present on blood cell surfaces and inhibits the terminal stage of the formation of membrane attack complexes by homologous complement activation. The tissue distribution of HRF20 was studied by immunohistochemical analysis using 1F5. HRF20 was predominantly expressed on endothelial cells of systemic arteries, veins and capillaries, as well as on the surface of cultured human umbilical vein endothelial cells. HRF20 was also detected, to a lesser extent, on the Schwann sheath of peripheral nerve fibres, ependymal cells and certain epithelial cells such as acinar cells of the salivary gland, bronchial epithelium, renal tubules and squamous epithelium. The distribution pattern of HRF20 differed somewhat from that of decay-accelerating factor (DAF), which is another membrane inhibitor of homologous complement activation.
通过1F5单克隆抗体（mAb）检测到的一种分子量为20,000的同源限制因子（HRF20）存在于血细胞表面，并通过同源补体激活抑制膜攻击复合物形成的终末阶段。使用1F5通过免疫组织化学分析研究了HRF20的组织分布。HRF20主要表达于全身动脉、静脉和毛细血管的内皮细胞以及培养的人脐静脉内皮细胞表面。在外周神经纤维的施万鞘、室管膜细胞和某些上皮细胞如唾液腺腺泡细胞、支气管上皮、肾小管和鳞状上皮中也能检测到HRF20，但程度较低。HRF20的分布模式与另一种同源补体激活的膜抑制剂衰变加速因子（DAF）略有不同。
